Biophytis has filed a patent for a composition that aims to prevent the loss of muscle strength in mammals during immobilization. The composition includes phytoecdysone or a semi-synthetic derivative, such as 20-hydroxyecdysone, and can be administered orally. The patent claims a method for preventing muscle strength loss by administering a pharmaceutically acceptable formulation containing these compounds. GlobalData’s report on Biophytis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Biophytis, cancer treatment biomarkers was a key innovation area identified from patents. Biophytis's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A composition for preventing muscle strength loss during immobilization
A recently filed patent (Publication Number: US20230158046A1) describes a method for preventing the loss of muscle strength during immobilization in mammals. The method involves administering a pharmaceutically acceptable formulation suitable for oral administration that includes either a phytoecdysone or a semisynthetic derivative of a phytoecdysone.
The formulation may specifically include 20-hydroxyecdysone or a semisynthetic derivative of 20-hydroxyecdysone. Additionally, the formulation may include a compound of general formula (I) or a compound chosen from a list of specific compounds. Another compound that may be included in the formulation is a compound of formula (II).
In humans, the phytoecdysones are administered at a dose ranging from 50 to 1000 milligrams per day. The formulation is administered during the period of immobilization and may continue to be administered until immobilization ends. Furthermore, the formulation may also be administered for a predetermined period after the immobilization period has ended.
This patent claims a method for preventing the loss of muscle strength during immobilization in mammals by administering a specific formulation orally. The formulation includes phytoecdysone or a semisynthetic derivative, such as 20-hydroxyecdysone, and may also include compounds of general formula (I) or specific compounds listed. The phytoecdysones are administered at a dose between 50 and 1000 milligrams per day in humans. The formulation is administered during immobilization and may continue until immobilization ends, with the option of also administering it for a predetermined period after immobilization has ended.
It is important to note that this summary is based solely on the claims provided in the patent and does not include any additional information or context.
To know more about GlobalData’s detailed insights on Biophytis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
